SLC5A2 and hydrops fetalis: Similarly, the EMPAG-HF (12) and Perez-Belmonte (19) studies showed larger absolute improvements in health status assessed using the VAS in the SGLT2 inhibitors group compared to the control group; however, these differences were not statistically significant.